Medipure Holdings Inc.
CNSX : MDH

Medipure Holdings Inc.

December 02, 2014 17:00 ET

Medipure Holdings Appoints Doctor Rakshit Kodekalra as Director of Quality Assurance and Control

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 2, 2014) - Medipure Holdings Inc. ("Medipure," or the "Company") (CSE:MDH) is pleased to announce that it has appointed Dr. Rakshit Kodekalra as the Company's Director of Quality Assurance and Control.

Dr. Kodekalra also serves as a Research Scientist at the Company. He possesses both a PhD in Agricultural Science from Germany's University of Hohenheim and a Master of Biochemistry from India's University of Mysore. In his role as Director of Quality Assurance and Control, Dr. Kodekalra will play a key role in furthering Medipure's goal of developing cannabinoid-based medicines as prescription pharmaceuticals.

Medipure's Quality Department is responsible for all activities that have impact on product quality and safety. The Department is also responsible for ensuring that all contracted services are verified to meet the quality standards established by both the Company and relevant regulators.

Medipure also announced today that its production and research teams are scheduled to participate in 'Fundamentals of Quality Assurance for Medical Marihuana - Good Production Practices' during the month of January. This intensive training course is hosted by Canada's Academy of Applied Pharmaceutical Sciences, and led by Dr. Peivand Pirouzi. The training will discuss best standards in production practices, quality system requirements, standard operating procedures, complaints, recalls, and laboratory testing. All attendees will receive a certificate of completion. Medipure anticipates that this training will further its objective of obtaining a license from Health Canada for the production and distribution of medical marihuana.

About Medipure Holdings Inc.

Medipure is developing an extensive network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. Medipure will attempt to bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of our products through rapid cost- effective product development, addressing market needs, and establishing strategic partnerships. Although Medipure has applied to Health Canada for a license to produce and distribute medical marihuana under the Marihuana for Medical Purposes Regulations, it has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada.

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy the securities in any jurisdiction. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act. This press release is not intended for distribution to U.S. newswire services, and should not be disseminated within the U.S.

Contact Information